{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:35:28Z","timestamp":1793039728546,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of global morbidity and mortality, with a significant societal and economic burden. Combined oral contraceptives (COCs) increase VTE risk by 2- to 6-fold, resulting in approximately 22,925 cases annually in the European Economic Area (EEA). Despite the high associated healthcare costs, which may reach 2.5 billion EUR annually, current international guidelines, including those from the World Health Organization (WHO) and the Faculty of Sexual and Reproductive Healthcare (FSRH), discourage routine thrombophilia screening prior to COC prescription, citing low cost-effectiveness, low prevalence of thrombophilia, and potential unintended consequences, such as reduced contraceptive use. Recent advancements in screening technology challenge these guidelines. The normalized Activated Protein C sensitivity ratio (nAPCsr) assay, a low-cost tool capable of detecting both inherited thrombophilia and acquired COC-induced activated protein C (APC) resistance, offers a promising strategy for targeted screening. Economic models estimate that implementing nAPCsr-based screening could prevent up to 13,500 VTE cases annually, leading to 1.5 billion EUR in annual healthcare savings. Additionally, nAPCsr-guided contraceptive counseling enables personalized decision-making, directing high-risk women toward safer contraceptive options, such as progestin-only pills or COCs containing natural estrogens (estradiol or estetrol), which present a lower thrombotic risk. This manuscript emphasizes the necessity of updating current prevention strategies by integrating innovative screening tools like the nAPCsr assay. By addressing both direct healthcare costs and indirect costs related to productivity loss and long-term complications, such a strategy could improve patient safety, reduce the financial burden on healthcare systems, and promote equitable access to safer contraceptive methods. Furthermore, targeted screening could alleviate the underrepresentation of high-risk women in current cost estimates and significantly mitigate the societal impact of COC-associated VTE. In light of these findings, reconsidering current policy recommendations appears essential to facilitate evidence-based, cost-effective prevention of COC-related thrombotic events, ultimately enhancing public health outcomes.<\/jats:p>","DOI":"10.3389\/fendo.2025.1559162","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:10:45Z","timestamp":1749687045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effective screening strategy to prevent venous thromboembolism in combined oral contraceptive users"],"prefix":"10.3389","volume":"16","author":[{"given":"Jonathan","family":"Douxfils","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12698","article-title":"Isth steering committee for world thrombosis day. Thrombosis: A Major Contributor to the Global Disease Burden","volume":"12","year":"2014","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S85635","article-title":"Review of the cost of venous thromboembolism","volume":"7","author":"Fernandez","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"B3","unstructured":"Assessment report for combined hormonal contraceptives containing medicinal products \u2014 Procedure number: emea\/H\/a-31\/1356\n          \n          2014"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-08-0670","article-title":"European union-28: an annualised cost-of-illness model for venous thromboembolism","volume":"115","author":"Barco","year":"2016","journal-title":"Thromb Haemostasis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e027514","DOI":"10.1161\/JAHA.122.027514","article-title":"Cost-of-illness analysis of long-term health care resource use and disease burden in patients with pulmonary embolism: insights from the prefer in vte registry","volume":"11","author":"Farmakis","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcz035","article-title":"Societal costs of venous thromboembolism and subsequent major bleeding events: A national register-based study","volume":"6","author":"Gustafsson","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e013086","DOI":"10.1136\/bmjopen-2016-013086","article-title":"Health-related quality of life after pulmonary embolism: A cross-sectional study","volume":"6","author":"Tavoly","year":"2016","journal-title":"BMJ Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e032146","DOI":"10.1161\/JAHA.123.032146","article-title":"Patient-reported outcomes in venous thromboembolism: A systematic review of the literature, current challenges, and ways forward","volume":"12","author":"Snyder","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010813.pub2","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28778","article-title":"Contemporary hormonal contraception and risk of venous thromboembolism","volume":"333","author":"Yonis","year":"2025","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2023.110310","article-title":"Comparison of estrogenic components used for hormonal contraception","volume":"130","author":"Stanczyk","year":"2024","journal-title":"Contraception"},{"key":"B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13697137.2023.2292066","article-title":"Low thrombin generation in postmenopausal women using estetrol","volume":"27","author":"Morimont","year":"2024","journal-title":"Climacteric"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2024.1395863","article-title":"Experts\u2019 View on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4)","volume":"5","author":"Creinin","year":"2024","journal-title":"Front Glob Womens Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph18010061","article-title":"Hormonal contraception and bone metabolism: emerging evidence from a systematic review and meta-analysis of studies on post-pubertal and reproductive-age women","volume":"18","author":"Tassi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B16","unstructured":"Contraceptive Use by Method 2019\n          \n          2019"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0182041","DOI":"10.1371\/journal.pone.0182041","article-title":"Risk prediction of developing venous thrombosis in combined oral contraceptive users","volume":"12","author":"McDaid","year":"2017","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102390","article-title":"Incidence rate of venous thrombosis in women switching combined oral contraceptives: A cohort study","volume":"8","author":"Khialani","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000208","article-title":"Hidden Costs Associated with Venous Thromboembolism: Impact of Lost Productivity on Employers and Employees","volume":"56","author":"Page","year":"2014","journal-title":"J Occup Environ Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13411","article-title":"Venous thromboembolism and subsequent permanent work-related disability","volume":"14","author":"Braekkan","year":"2016","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1769592","article-title":"Venous thromboembolism in women of childbearing age: insights from the start registry","volume":"123","author":"Grandone","year":"2023","journal-title":"Thromb Haemostasis"},{"key":"B23","unstructured":"Fsrh Guideline - Combined Hormonal Contraception (Amended October 2023)\n          \n          2019"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16666","article-title":"The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk","volume":"191","author":"Khialani","year":"2020","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15661","article-title":"Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: systematic review and meta-analysis","volume":"20","author":"Wiegers","year":"2022","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18331","article-title":"Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis","volume":"199","author":"Abdulrehman","year":"2022","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0124719","DOI":"10.1371\/journal.pone.0124719","article-title":"The italian start-register on anticoagulation with focus on atrial fibrillation","volume":"10","author":"Antonucci","year":"2015","journal-title":"PloS One"},{"key":"B28","unstructured":"Medical Eligibility Criteria for Contraceptive Use\n          \n          2015"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American society of hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"U.S. Medical eligibility criteria for contraceptive use, 2024","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the etp-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"Douxfils","year":"2020","journal-title":"Clin Chem Lab Med: CCLM\/FESCC"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2024.110727","article-title":"Lower reporting of venous thromboembolisms events with natural estrogen-based combined oral contraceptives compared to ethinylestradiol-containing pills: A disproportionality analysis of the eudravigilance database","volume":"142","author":"Didembourg","year":"2025","journal-title":"Contraception"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1428597","article-title":"Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis","volume":"15","author":"Douxfils","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1753511","article-title":"Laboratory testing for the evaluation of phenotypic activated protein C resistance","volume":"48","author":"Morimont","year":"2022","journal-title":"Semin Thromb Hemostasis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20190115","DOI":"10.3390\/jpm9010004","article-title":"Re-examining genetic screening and oral contraceptives: A patient-centered review","volume":"9","author":"Hiedemann","year":"2019","journal-title":"J Pers Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1641152","article-title":"Type of combined contraceptives, factor V leiden mutation and risk of venous thromboembolism","volume":"118","author":"Hugon-Rodin","year":"2018","journal-title":"Thromb Haemostasis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2013.211","article-title":"Inherited risk factors for venous thromboembolism","volume":"11","author":"Martinelli","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-02-0141","article-title":"Classic thrombophilic gene variants","volume":"114","author":"Mannucci","year":"2015","journal-title":"Thromb Haemostasis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1714140","article-title":"Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk","volume":"46","author":"Douxfils","year":"2020","journal-title":"Semin Thromb Hemostasis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100155","article-title":"Hormonal therapies and venous thrombosis: considerations for prevention and management-a reappraisal","volume":"7","author":"Douxfils","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13427","article-title":"Assessment of acquired activated protein C resistance with the fibwave and comparison with the etp-based apc resistance","volume":"43","author":"Evrard","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac511","article-title":"Low thrombin generation in users of a contraceptive containing estetrol and drospirenone","volume":"108","author":"Morimont","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1055\/a-1153-5824","article-title":"Can we measure the individual prothrombotic or prohemorrhagic tendency by global coagulation tests","volume":"40","author":"Reda","year":"2020","journal-title":"Hamostaseologie"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-10-0806","article-title":"Detection of procoagulant imbalance. Modified Endogenous Thrombin Potential with Results Expressed as Ratio of Values with-to-without Thrombomodulin","volume":"117","author":"Tripodi","year":"2017","journal-title":"Thromb Haemostasis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e12684","DOI":"10.1002\/rth2.12684","article-title":"Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated st genesia system","volume":"6","author":"Morimont","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B50","unstructured":"Gosset\n              O\n            \n          \n          La soci\u00e9t\u00e9 Li\u00e9geoise Qualiblood Signe Avec Le Fran\u00e7ais Diagnostica Stago: L\u2019\u00c9cho \u2014 M\u00e9diafin\n          \n          2025"},{"key":"B51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejim.2017.05.019","article-title":"Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk","volume":"42","author":"Stegeman","year":"2017","journal-title":"Eur J Internal Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.13","article-title":"Higher frequency of genetic variants conferring increased risk for adrs for commonly used drugs treating cancer, aids and tuberculosis in persons of african descent","volume":"14","author":"Aminkeng","year":"2014","journal-title":"Pharmacogen J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_120","article-title":"Genetic risk factors in venous thromboembolism","volume":"906","author":"Hotoleanu","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-017-0318-x","article-title":"Economic evaluations of thrombophilia screening prior to prescribing combined oral contraceptives: A systematic and critical review","volume":"15","author":"Vernon","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for vte disease: second update of the chest guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the isth ssc subcommittee on lupus anticoagulant\/antiphospholipid antibodies","volume":"19","author":"Ninivaggi","year":"2021","journal-title":"J Thromb Haemostasis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14470","article-title":"Assessment of the analytical performances and sample stability on st genesia system using the stg-drugscreen application","volume":"17","author":"Douxfils","year":"2019","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B59","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jth.14745","article-title":"Proof of concept of a new scale for the harmonization and the standardization of the etp-based apc resistance","volume":"18","author":"Morimont","year":"2020","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the editors-in-chief in response to the article of abou-ismail, et\u00a0al. Entitled \u201cEstrogen and Thrombosis: A Bench to Bedside Review\u201d (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0037-1613145","article-title":"Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based apc resistance test","volume":"88","author":"Curvers","year":"2002","journal-title":"Thromb Haemostasis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13349","article-title":"Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: A systematic review and meta-analysis","volume":"14","author":"van Vlijmen","year":"2016","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archinte.160.1.49","article-title":"Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects","volume":"160","author":"Bloemenkamp","year":"2000","journal-title":"Arch Internal Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1768712","article-title":"Antithrombin deficiency is associated with prothrombotic plasma fibrin clot phenotype","volume":"123","author":"Natorska","year":"2023","journal-title":"Thromb Haemostasis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1160\/TH15-06-0478","article-title":"Uncertain thrombophilia markers","volume":"115","author":"Franchini","year":"2016","journal-title":"Thromb Haemostasis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2180","article-title":"Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma\u2019 Levels","volume":"106","author":"Uitte de Willige","year":"2005","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554055","article-title":"Fibrinogen gamma\u2019 Increases the sensitivity to activated protein C in normal and factor V leiden plasma","volume":"124","author":"Omarova","year":"2014","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e0141491","DOI":"10.1371\/journal.pone.0141491","article-title":"Thrombin generating capacity and phenotypic association in abo blood groups","volume":"10","author":"Kremers","year":"2015","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1055\/a-1698-6717","article-title":"The risk of venous thromboembolism attributed to established prothrombotic genotypes","volume":"122","author":"Evensen","year":"2022","journal-title":"Thromb Haemostasis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.05.004","article-title":"The F11 rs2289252 polymorphism is associated with fxi activity levels and aptt ratio in women with thrombosis","volume":"130","author":"Lunghi","year":"2012","journal-title":"Thromb Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.248492","article-title":"A genome-wide association study identifies kng1 as a genetic determinant of plasma factor xi level and activated partial thromboplastin time","volume":"32","author":"Sabater-Lleal","year":"2012","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12833","article-title":"Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the pilgrim study","volume":"91","author":"Suchon","year":"2017","journal-title":"Clin Genet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.01.019","article-title":"Meta-analysis of 65,734 individuals identifies tspan15 and slc44a2 as two susceptibility loci for venous thromboembolism","volume":"96","author":"Germain","year":"2015","journal-title":"Am J Hum Genet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e29186","DOI":"10.1371\/journal.pone.0029186","article-title":"Determinants of sustained viral suppression in hiv-infected patients with self-reported poor adherence to antiretroviral therapy","volume":"7","author":"Glass","year":"2012","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0207671","DOI":"10.1371\/journal.pone.0207671","article-title":"Characterization of adme genes variation in roma and 20 populations worldwide","volume":"13","author":"Skaric-Juric","year":"2018","journal-title":"PloS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2010.73","article-title":"Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements","volume":"55","author":"Ross","year":"2010","journal-title":"J Hum Genet"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1715793","article-title":"Hormonal contraceptives and the risk of venous thrombosis","volume":"46","author":"Khialani","year":"2020","journal-title":"Semin Thromb Hemostasis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1559162\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:10:48Z","timestamp":1749687048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1559162\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":77,"alternative-id":["10.3389\/fendo.2025.1559162"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1559162","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1559162"}}